OTCMKTS:INTI Inhibitor Therapeutics Q4 2024 Earnings Results & Report $0.08 0.00 (0.00%) As of 11/10/2026 11:29 AM Eastern Inhibitor Therapeutics reported Q4 2024 earnings on March 28, 2025. The company reported EPS of -$0.01. Research:ProfileEarnings History Earnings Announcement Details QuarterQ4 2024Report DateMarch 28, 2025TimeAfter Market Closes Inhibitor Therapeutics EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInhibitor Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Inhibitor Therapeutics Q4 2024 Earnings FAQ Did Inhibitor Therapeutics beat earnings estimates for Q4 2024? Inhibitor Therapeutics (OTCMKTS:INTI) reported earnings of -$0.01 per share for Q4 2024. The report was announced on Friday, March 28, 2025. Inhibitor Therapeutics Earnings HeadlinesInhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingSeptember 8, 2026 | globenewswire.comCheckpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsightAugust 19, 2026 | finance.yahoo.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 14 at 1:00 AM | Paradigm Press (Ad)Blacksmith Medicines Announces Publication in Journal of Medicinal Chemistry Highlighting Discovery of a Non-Hydroxamate LpxC InhibitorAugust 5, 2026 | finance.yahoo.comInhibitor Therapeutics Advances Gorlin Syndrome Itraconazole ProgramJune 18, 2026 | theglobeandmail.comInhibitor Therapeutics Sues Investor Over Failed Financing DealApril 1, 2026 | tipranks.comSee More Inhibitor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibitor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibitor Therapeutics and other key companies, straight to your email. Email Address About Inhibitor TherapeuticsInhibitor Therapeutics (OTCMKTS:INTI) (OTCMKTS:INTI) is a clinical-stage pharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s approach has centered on evaluating established compounds for potential use in oncology. Its primary development program has involved itraconazole, an antifungal medication that is being investigated for potential anticancer applications. Inhibitor Therapeutics has studied itraconazole in connection with cancers including prostate cancer and non-small cell lung cancer. These uses remain investigational and are distinct from the drug’s approved antifungal indications. The company’s activities have primarily consisted of pharmaceutical research, clinical development and efforts to advance its oncology candidates toward potential regulatory approval. Publicly available information about its commercial operations, geographic reach and current leadership is limited.View Inhibitor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
